James Powell, MD
Endocrinology, Diabetes & Metabolism · Hattiesburg, MSNPI 1164523932
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,800 of the $88,351 with a category attached, or 83.5%. Amgen accounts for 91.0% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $60,574 and has fallen 97.8% since, to $1,313 in 2025.
Across 642 payments — averaging $137.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$80K
- Lilly USA, LLC$843
- Novo Nordisk$811
- Sanofi-aventis U.S. LLC$807
- Abbott$802
- Boehringer Ingelheim$642
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$73,80084%
- Travel & lodging$3,9965%
- Food & beverage$10,55512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 173 | $80,416 |
| Lilly USA, LLC | 54 | $843 |
| Novo Nordisk | 55 | $811 |
| Sanofi-aventis U.S. LLC | 43 | $807 |
| Abbott | 44 | $802 |
| Boehringer Ingelheim | 38 | $642 |
| Dexcom, Inc. | 29 | $605 |
| AbbVie | 32 | $517 |
| AstraZeneca | 18 | $265 |
| Medtronic(2 entities) | 16 | $217 |
| Bayer | 10 | $173 |
| Radius Health, Inc. | 10 | $170 |
| Insulet Corporation | 7 | $157 |
| Xeris Pharmaceuticals, Inc. | 7 | $153 |
| Tandem Diabetes Care, Inc. | 8 | $135 |
| Merck | 9 | $127 |
| Novartis | 7 | $116 |
| Pfizer | 7 | $115 |
| Johnson & Johnson | 7 | $107 |
| Lifescan, Inc. | 8 | $107 |
| Sequel Med Tech, LLC | 5 | $102 |
| BD | 6 | $98 |
| Corcept Therapeutics | 6 | $93 |
| Ascendis Pharma Endocrinology Inc | 5 | $91 |
| IBSA Pharma Inc. | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 5 | $87 |
| BETA Bionics, Inc. | 3 | $85 |
| Amarin Pharma, Inc. | 6 | $85 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| GRT US Holding, Inc. | 4 | $59 |
| Amneal Pharmaceuticals LLC | 4 | $53 |
| RGH Enterprises LLC | 1 | $40 |
| Shire North American Group Inc | 2 | $32 |
| Averitas Pharma Inc. | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,351 in reported general payments places this provider in the 80th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 105 | $124,149 |
| SynthroidLevothyroxine Sodium | 1,158 | $64,833 |
| TymlosAbaloparatide | 21 | $56,178 |
| JardianceEmpagliflozin | 50 | $43,603 |
| OzempicSemaglutide | 37 | $37,098 |
| TrulicityDulaglutide | 29 | $31,402 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 41 | $21,485 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $12,764 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $12,344 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,381 |
| Repatha SureclickEvolocumab | 17 | $9,271 |
| Novolog FlexpenInsulin Aspart | 55 | $7,179 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $7,146 |
| Levothyroxine Sodium | 1,120 | $7,065 |
| NovologInsulin Aspart | 29 | $4,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $843 | $155,551134 claims |
| AbbVieSynthroid | $517 | $64,8331,158 claims |
| Radius Health, Inc.Tymlos | $170 | $56,17821 claims |
| Boehringer IngelheimJardiance | $642 | $43,60350 claims |
| Novo NordiskOzempic, Novolog | $811 | $42,01066 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $7,0651,120 claims |
| PfizerLevoxyl | $115 | $43221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Hattiesburg
- Richard GallowayHattiesburg$109K
- Jaya NaranHattiesburg$3K
- Aboorva Kambiliampatti SudhakarHattiesburg$1K
- Daniel McCallHattiesburg$1K
- Dana DaleHattiesburg$300
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.